Expertise in
27
conditions

Dr. Rahul R. Aggarwal

Cardiology
Office
4741 Military Trl Ste 100, 
Jupiter,, FL 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
17 Years of Experience
Referral may be required
Before you request
Expertise in
27
conditions
Office
4741 Military Trl Ste 100, 
Jupiter,, FL 

Overview

Rahul Aggarwal is a Cardiologist practicing medicine in Jupiter,, Florida. He has been practicing medicine for over 17 years.

Dr. Aggarwal is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Coronary Heart Disease, Angina, Hypertension, Orchiectomy, and Heart Bypass Surgery.

He is actively involved in clinical research, co-authoring 289 peer reviewed articles and participating in 40 clinical trials. Dr. Aggarwal is currently accepting new patients.

Graduate Year

2009

Specialties

Cardiology

Licenses

Internal Medicine in FL

Hospital Affiliations

Palm Beach Gardens Medical Center
Jupiter Medical Center
Cleveland Clinic Martin North Hospital

Languages Spoken

English
Hindi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Northwell Health
  • INSURANCE PLAN
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 23 Less Insurance Carriers -

Locations

Office
4741 Military Trl Ste 100, Jupiter,, FL 33458

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

33 Clinical Trials

A Phase 2 Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) in Patients With Prostate Cancer on Active Surveillance
A Phase 2 Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) in Patients With Prostate Cancer on Active Surveillance
Enrollment Status: Recruiting
Publish Date: May 18, 2026
Intervention Type: Drug, Procedure
Study Drug: Hyperpolarized Carbon C 13 Pyruvate
Study Phase: Phase 2
A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer
A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer
Enrollment Status: Recruiting
Publish Date: April 30, 2026
Intervention Type: Drug, Procedure
Study Drugs: Pyruvate, Hyperpolarized 13C 15N2-Urea
Study Phase: Early Phase 1
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors
Phase I Clinical Trial of M6620 (VX-970, Berzosertib) in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Drug
Study Drugs: Berzosertib, Irinotecan Hydrochloride
Study Phase: Phase 1
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug
Study Drug: Adavosertib
Study Phase: Phase 2
A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
A Phase 2 Study of BET Bromodomain Inhibitor ZEN-3694 in Combination With Enzalutamide Plus Pembrolizumab in Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2026
Intervention Type: Drug, Biological
Study Drugs: BET Bromodomain Inhibitor ZEN-3694, Enzalutamide, Pembrolizumab
Study Phase: Phase 2
Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) as a Diagnostic and Response Monitoring Imaging Tool in Advanced Prostate Cancer
Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) as a Diagnostic and Response Monitoring Imaging Tool in Advanced Prostate Cancer
Enrollment Status: Suspended
Publish Date: June 23, 2026
Intervention Type: Procedure, Drug
Study Drug: Hyperpolarized C13
Study Phase: Phase 2
A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
A Multi-arm, Phase 2 Study to Evaluate the Safety and Efficacy of Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2026
Intervention Type: Drug
Study Drug: IMMU-132
Study Phase: Phase 2
A Phase 2 Study of 68Ga-PSMA-11 PET in Patients With Metastatic Castration Resistant Prostate Cancer
A Phase 2 Study of 68Ga-PSMA-11 PET in Patients With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 15, 2026
Intervention Type: Drug, Procedure
Study Drug: 68Ga-PSMA-11
Study Phase: Phase 2
Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype
Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype
Enrollment Status: Completed
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drugs: Talabostat Mesylate, Pembrolizumab
Study Phase: Phase 1/Phase 2
Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies
Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: April 23, 2026
Intervention Type: Drug
Study Drugs: ATR Kinase Inhibitor AZD6738, Olaparib
Study Phase: Phase 2
View 8 Less Clinical Trials

289 Total Publications

Evaluation of an Artificial Intelligence Communication Platform for Racial Biases in Pretest Education About Prostate Cancer Germline Testing.
Evaluation of an Artificial Intelligence Communication Platform for Racial Biases in Pretest Education About Prostate Cancer Germline Testing.
Journal: JCO clinical cancer informatics
Published: July 20, 2026
Similar Doctors
Expertise in
45
conditions
Expertise in
45
conditions
Referral may be required
Before you request

Digital Echo LLC

600 University Blvd Ste 200, 
Jupiter,, FL 
 (0.1 miles away)
561-627-2210
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Gonzalo Loveday is a Cardiologist practicing medicine in Jupiter,, Florida. Dr. Loveday is highly rated in 45 conditions, according to our data. His clinical expertise encompasses Acute Coronary Syndrome, Angina, Atherosclerosis, Coronary Heart Disease, and Pacemaker Implantation. Dr. Loveday is currently accepting new patients.

Expertise in
24
conditions
Dr. Jerry D. Estep
Cardiology | Interventional Cardiology
Expertise in
24
conditions
Dr. Jerry D. Estep
Cardiology | Interventional Cardiology
Referral may be required

Cleveland Clinic Florida

2950 Cleveland Clinic Blvd, 
Weston, FL 
 (60.8 miles away)
954-659-5000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jerry Estep is a Cardiologist and an Interventional Cardiologist practicing medicine in Weston, Florida. Dr. Estep is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Heart Failure, Cardiac Amyloidosis, Cardiogenic Shock, Heart Transplant, and Endoscopy. Dr. Estep is currently accepting new patients.

Expertise in
41
conditions
Expertise in
41
conditions
Referral may be required
Before you request

Digital Echo LLC

600 University Blvd Ste 200, 
Jupiter, FL 
 (0.1 miles away)
561-627-2210
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Utpal Sagar is a Cardiologist practicing medicine in Jupiter, Florida. Dr. Sagar is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Angina, Aortic Valve Stenosis, High Cholesterol, and Glucocorticoid-Remediable Aldosteronism. Dr. Sagar is currently accepting new patients.

Frequently Asked Questions about Dr. Rahul R. Aggarwal

How do I make an appointment with Dr. Rahul R. Aggarwal?

You can book an appointment with Dr. Rahul R. Aggarwal by calling their office at 561-627-3130. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rahul R. Aggarwal a top-rated expert for Coronary Heart Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rahul R. Aggarwal is classified as an Distinguished expert for Coronary Heart Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rahul R. Aggarwal specialize in?

While Dr. Rahul R. Aggarwal is a Cardiology, they have specific expertise in Coronary Heart Disease, Angina, and Hypertension. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Cardiology.

Does Dr. Rahul R. Aggarwal participate in research or clinical trials?

Yes. Dr. Rahul R. Aggarwal has published 289 articles and abstracts on conditions like Coronary Heart Disease. You can view a list of Dr. Rahul R. Aggarwal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rahul R. Aggarwal accept my insurance?

Dr. Rahul R. Aggarwal accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 561-627-3130 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Aggarwal's expertise for a condition
ConditionClose
    View All 22 Advanced Conditions
    View All 61 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile